BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
1285 results:

  • 1. Telangiectasias induced by combination tucatinib and ado-trastuzumab emtansine in a patient with metastatic breast cancer.
    Rodriguez GF; Shah A; Maderal AD
    Breast Dis; 2024; 43(1):61-64. PubMed ID: 38578876
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [The effect of deep neuromuscular block combined with low pneumoperitoneum pressure on postoperative pain in patients undergoing laparoscopic radical colorectal surgery].
    Li HX; Xu X; Tan PX; Wang TH; Li BL; Zheng H; Yan T
    Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(13):1057-1063. PubMed ID: 38561301
    [No Abstract]    [Full Text] [Related]  

  • 3. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
    Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Associations of circulating advanced glycation end products and their soluble receptors with cancer risk: A systematic review and meta-analysis of observational studies.
    Hajizadeh-Sharafabad F; Shojaei-Zarghani S; Sharifi-Zahabi E; Gerami F; Pashaei MR
    Glycoconj J; 2024 Feb; 41(1):35-46. PubMed ID: 38498243
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Trastuzumab plus pertuzumab for her2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
    Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
    Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Synergistic antitumor activity between her2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
    Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
    Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. her2 targeted therapy in colorectal cancer: Current landscape and future directions.
    Chen N; He L; Zou Q; Deng H
    Biochem Pharmacol; 2024 May; 223():116101. PubMed ID: 38442793
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal her2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
    Connolly RM; Wang V; Hyman DM; Grivas P; Mitchell EP; Wright JJ; Sharon E; Gray RJ; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Wang J; Wisinski KB; Tricoli JV; Conley BA; Harris LN; Arteaga CL; O'Dwyer PJ; Chen AP; Flaherty KT
    Clin Cancer Res; 2024 Apr; 30(7):1273-1280. PubMed ID: 38433347
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Current advances in targeted therapy for metastatic colorectal cancer - Clinical translation and future directions.
    Johnson D; Chee CE; Wong W; Lam RCT; Tan IBH; Ma BBY
    Cancer Treat Rev; 2024 Apr; 125():102700. PubMed ID: 38422896
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The Role of Beclin 1 and her2 in colorectal Carcinoma; An Immunohistochemical Study.
    Gadallah MS; Dawood M; Abdou A
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):617-626. PubMed ID: 38415549
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. her2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
    Prete AA; Angerilli V; Bergamo F; Vettore V; De Toni C; Intini R; Cerma K; Ricagno G; Cerantola R; Perissinotto E; De Rosa A; Ceccon C; Gasparello J; Denaro L; D'Amico A; Chioffi F; Carcea E; Fassan M; Lonardi S
    Br J Cancer; 2024 May; 130(8):1316-1323. PubMed ID: 38347094
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. RAS/RAF Comutation and erbb2 Copy Number Modulates her2 Heterogeneity and Responsiveness to her2-directed Therapy in colorectal cancer.
    Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
    Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for her2-positive tumors.
    Zhao S; Qiu Y; Yuan M; Wang Z
    Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [A Case of Advanced Recurrent Rectal cancer Successfully Treated by Rechallenge Therapy with an Anti-Epidermal Growth Factor Receptor(EGFR)Drug].
    Sakuma T; Shibutani M; Fukuoka T; Kasashima H; Nishiyama M; Fukui Y; Natsuki S; Nishiyama T; Maruo K; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Maeda K
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1504-1506. PubMed ID: 38303322
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Impact of weight loss on cancer-related proteins in serum: results from a cluster randomised controlled trial of individuals with type 2 diabetes.
    Bull CJ; Hazelwood E; Legge DN; Corbin LJ; Richardson TG; Lee M; Yarmolinsky J; Smith-Byrne K; Hughes DA; Johansson M; Peters U; Berndt SI; Brenner H; Burnett-Hartman A; Cheng I; Kweon SS; Le Marchand L; Li L; Newcomb PA; Pearlman R; McConnachie A; Welsh P; Taylor R; Lean MEJ; Sattar N; Murphy N; Gunter MJ; Timpson NJ; Vincent EE
    EBioMedicine; 2024 Feb; 100():104977. PubMed ID: 38290287
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212).
    Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
    Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance.
    Kusumaningrum AE; Makaba S; Ali E; Singh M; Fenjan MN; Rasulova I; Misra N; Al-Musawi SG; Alsalamy A
    Cell Biochem Funct; 2024 Jan; 42(1):e3906. PubMed ID: 38269502
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Novel immunotherapies for breast cancer: Focus on 2023 findings.
    Lan HR; Chen M; Yao SY; Chen JX; Jin KT
    Int Immunopharmacol; 2024 Feb; 128():111549. PubMed ID: 38266449
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
    Bando H; Yamaguchi K; Mitani S; Sawada K; Mishima S; Komine K; Okugawa Y; Hosoda W; Ebi H
    Cancer Sci; 2024 Mar; 115(3):1014-1021. PubMed ID: 38263580
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 65.